Biblio

Author Title [ Type

] Year

Filters: Author is Kumar, Deepak [Clear All Filters]

Journal Article

Kumar D, Gupta S, Yang Y, Forsyth NR. α V β 5 and CD44 Are Oxygen-Regulated Human Embryonic Stem Cell Attachment Factors. Biomed Res Int. 2013;2013:729281.

Karvas RM, Khan SA, Verma S, Yin Y, Kulkarni D, Dong C, Park K-M, Chew B, Sane E, Fischer LA, et al. Stem-cell-derived trophoblast organoids model human placental development and susceptibility to emerging pathogens. Cell Stem Cell. 2022;29(5):810-825.e8.

Kashyap A, Tripathi G, Tripathi A, Rao R, Kashyap M, Bhat A, Kumar D, Rajhans A, Kumar P, Chandrashekar DShimoga, et al. RNA splicing: a dual-edged sword for hepatocellular carcinoma. Med Oncol. 2022;39(11):173.

Hajra A, Safiriyu I, Balasubramanian P, Gupta R, Chowdhury S, Prasad AJ, Kumar A, Kumar D, Khan B, Bilberry RSF, et al. Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension. Curr Probl Cardiol. 2022:101236.

Shekhar S, Panwar R, Prasad SChandra, Kumar D, Rustagi A. Overexpression of flowering locus D (FLD) in Indian mustard (Brassica juncea) enhances tolerance to Alternaria brassicae and Sclerotinia sclerotiorum. Plant Cell Rep. 2023.

Panwar V, Singh A, Bhatt M, Tonk RK, Azizov S, Raza ASaquib, Sengupta S, Kumar D, Garg M. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct Target Ther. 2023;8(1):375.

Ahmad I, Goel D, Ghosh A, Kapoor H, Kumar D, Ramesh K, Ashley B, Deepika K, Shastry A, Faruq M. Generation of two induced pluripotent stem cell (iPSC) lines from patients with Duchenne muscular dystrophy (IGIBi006-A and IGIBi008-A) carrying exonic deletions in the dystrophin gene. Stem Cell Res. 2022;64:102927.

Kumar D, Hussain A, Srivastava AK, Mukerji M, Mukherjee O, Faruq M. Generation of three spinocerebellar ataxia type-12 patients derived induced pluripotent stem cell lines (IGIBi002-A, IGIBi003-A and IGIBi004-A). Stem Cell Res. 2018;31:216-221.

Kumar S, Ali I, Abbas F, Rana A, Pandey S, Garg M, Kumar D. design, pharmacophore-based screening, and molecular docking studies reveal that benzimidazole-1,2,3-triazole hybrids as novel EGFR inhibitors targeting lung cancer. J Biomol Struct Dyn. 2023:1-23.